Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Ocrelizumab
Sponsor: Hoffmann-La Roche
Active, not recruiting

Author:

Published July 16, 2022

Categorized as Clinical Trials, Multiple Sclerosis (MS)

Impact of Core Performance on Functional Parameters in Multiple Sclerosis

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

About the blog

Health Information Technology System News and Healthcare Advances. Also Learn More about the Field of Health Data Scientists

Please leave this field empty

Health Data Scientist

Don’t miss these tips!

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.

New Product Review

Evaluate New Health Applications. Be the first to decide. Your opinion matters.

Survey